Drugs / MEN2501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07226427 | Jan 2026 → Dec 2027 expected | refractory malignant neoplasm | Stemline Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEN2501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07226427 ↗ |
| Action | Inhibit | “MEN2501, a KIF18A Inhibitor” NCT07226427 ↗ |
| Route | Oral | “Oral tablet” NCT07226427 ↗ |
| Target | KIF18A | “MEN2501, a KIF18A Inhibitor” NCT07226427 ↗ |